KPRX Live signals | Maximize Profits with Getagraph.com

BUY 104514 min ago

@ $0.800

Issued: 7 Feb 2024 @ 13:05

Return: -38.71%

Previous signal: Feb 7 - 11:44

Previous signal: Sell

Return: -5.88 %

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States...

Stats
Today's Volume	44 417.00
Average Volume	1.66M
Market Cap	12.87M
EPS	$-0.470 ( 2024-03-28 )
Next earnings date	( $-0.420 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.180
ATR14	$0.00700 (1.43%)

Insider Trading

Date	Person	Action	Amount	type
2023-09-29	Tosca Melissa	Buy	60 000	Stock Option (right to buy)
2023-09-29	Tosca Melissa	Buy	30 000	Common Stock
2023-09-29	Daniels Eric Joseph	Buy	125 000	Stock Option (right to buy)
2023-09-29	Daniels Eric Joseph	Buy	62 500	Common Stock
2023-09-29	Strem Brian M.	Buy	150 000	Stock Option (right to buy)

INSIDER POWER
100.00
Last 91 transactions
Buy: 1 933 640 \| Sell: 3 426 001

Volume Correlation

Long: -0.14 (neutral)

Short: 0.72 (moderate)

Signal:(43.184) Neutral

Kiora Pharmaceuticals, Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Kiora Pharmaceuticals, Correlation - Currency/Commodity

0.38
( neutral )

0.27
( neutral )

0.00
( neutral )

-0.32
( neutral )

Kiora Pharmaceuticals, Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-62 424.00 (0.00 %)
EPS:	$-2.58

Q4	2023
Revenue:	$0
Gross Profit:	$-7 935.00 (0.00 %)
EPS:	$-0.290

Q3	2023
Revenue:	$0
Gross Profit:	$-42 382.00 (0.00 %)
EPS:	$-0.810

Q2	2023
Revenue:	$0
Gross Profit:	$-56 698.00 (0.00 %)
EPS:	$-0.790

Financial Reports:

No articles found.

Kiora Pharmaceuticals,

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.